Spine surgeon Frank Cammisa, MD, was named chief medical officer of Orthobond.
He is chief emeritus of spine surgery at Hospital for Special Surgery and is a professor at Weill Cornell Medical College, both in New York City. At Orthobond, he will lead clinical research and commercial applications into the company's covalently-bound antimicrobial surface technology, according to a Dec. 9 news release.
"Device designs have seen significant advances in the past decade; however, the need to eliminate bacterial contamination of the surgical instruments and implants in the operating room environment has not been solved," Dr. Cammisa said in the release. "Orthobond’s technology shows great efficacy against the most common strains of bacteria."
Orthobond's antimicrobial nanosurfaces are designed to have broad applications in the medical device industry. It's the first company to use nanoscale surface modifications that can permanently bind to any surface, the release said.